Sage Therapeutics’ Dalzanemdor Fails in Alzheimer’s, Hopes Now Rest on Huntington’s Disease Trial

Dalzanemdor's Failure in Alzheimer's Disease:
Sage Therapeutics announced that dalzanemdor, an investigational NMDA receptor positive allosteric modulator, failed to meet its primary endpoint in the Phase 2 LIGHTWAVE study for mild cognitive impairment and mild dementia in Alzheimer's disease.

Shift in Focus to Huntington's Disease:
Following the failure in Alzheimer's disease, Sage Therapeutics is now focusing on the ongoing Phase 2 DIMENSION study evaluating dalzanemdor in cognitive impairment associated with Huntington's disease, with topline data expected later this year.

Previous Results in Huntington's Disease:
The Phase 2 SURVEYOR study demonstrated significant cognitive impairment in Huntington's disease patients compared to healthy individuals but did not show a statistically significant difference between dalzanemdor and placebo in improving cognitive function.

Safety and Tolerability:
Dalzanemdor was generally well-tolerated in both the LIGHTWAVE and SURVEYOR studies, with no new safety signals observed.

Future Prospects:
The success of dalzanemdor now heavily depends on the outcomes of the DIMENSION study in Huntington's disease, as Sage Therapeutics has discontinued its development in Alzheimer's disease.